You searched for "macular oedema"
Diabetes macular oedema in pregnancy self-resolving postpartum
*Equally contributing co-first authors. Diabetic macular oedema (DMO) is a common clinical presentation to ophthalmology clinics. Ample evidence exists for management of DMO in non-pregnant patients. However, there is a paucity of evidence on the optimal management of DMO in...
DRIL after macular oedema treatment in BRVO
The authors report the analysis of a single-site, retrospective, cross-sectional study to evaluate the association between disorganisation of the retinal inner layers (DRIL) and visual acuity (VA) after anti-VEGF treatment for macular oedema (MO) due to branch retinal vein occlusion...
Bromfenac versus betamethasone in diabetic macular oedema
This is a randomised, prospective, single-centre trial in patients diagnosed with diabetic macular oedema (DMO) with central subfield thickness (CST) of 250-500µm, who refused anti-VEGF treatment. Nineteen eyes of 19 patients were randomised to bromfenac (BF) or betamethasone (BM) drops,...
Prophylaxis for clinical macular oedema after phacoemulsification
The authors report on a retrospective cohort study looking at three different prophylaxis methods for macular oedema after cataract surgery: 1) Topical prednisolone acetate (PA) alone; 2) Topical PA in combination with non-steroidal anti-inflammatory drug (NSAID); 3) Intraoperative subconjunctival injection...
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema
Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...
Intravitreal dexamethasone implant for diabetic macular oedema
The authors report on the three-year outcomes of the Ozurdex Dexamethasone (DEX) intravitreal implant multi-centre trial for the treatment of diabetic macular oedema (DME). Patients with DME (best-corrected vision of 20/50 to 20/200 and central retinal thickness of ≥300µm) were...
Avastin vs. Volon A for diabetic macular oedema
This prospective randomised interventional clinical trial compared 30 diabetic patients with macular oedema treated with either intravitreal injections of bevacizumab (Avastin) or triamcinolone (Volon A). One group initially received three injections of 2.5 mg Avastin in monthly intervals whilst the...
Macular oedema after cataract surgery in diabetic patients
The authors describe a multi-centre prospective observational study of 293 participants that underwent cataract surgery who all had diabetic retinopathy without definite central-involved macular oedema. Forty-five clinical sites took part throughout the United States. Patients were eligible if there was...
Rebound phenomenon after IVT triamcinolone acetonide for macular oedema
In this retrospective study, the authors report the rebound phenomenon after intravitreal triamcinolone acetonide (IVTA) injection for macular oedema secondary to diabetic retinopathy (DR) and central (CRVO) or branch retinal vein occlusion (BRVO). The incidence of a rebound phenomenon was...
OCT biomarkers in asymmetric anti-VEGF response in bilateral diabetic macular oedema
This study aimed to identify optical coherence tomography (OCT) biomarkers for predicting response to anti-VEGF treatment in diabetic macular oedema (DMO). Bilateral DMO patients with asymmetric response to a loading dose of anti-VEGF (ranibizumab / aflibercept) treatment were retrospectively studied....Pathophysiology of diabetic macular oedema: why combination therapy may be better
The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...
